Icagen Inc.'s potential $1 billion-plus deal with Pfizer Inc. to develop sodium ion channel modulators for pain took the hurt out of a Phase III setback with senicapoc for sickle cell disease and the loss of two other pharma partners recently. (BioWorld Today) Read More
